Ratio, Ionetix ink separate deals to speed production of in-demand radiopharmaceutical isotopes
Ratio Therapeutics and Ionetix have inked separate deals to boost the production of the medical radioisotope actinium-225, which is helping fuel the explosive growth of radiopharmaceuticals in cancer treatment.
